Stockscreener 앱 받기
1.25
8.70%
0.10
Renovorx Inc 주식(RNXT)의 최신 뉴스
RenovoRx Expands Phase III Pancreatic Cancer Trial to Major Research Network, Accelerating Patient Enrollment - StockTitan
RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET - Markets Insider
RenovoRx to Host Fireside Chat on Phase III Cancer Trial Progress and 2025 Strategic Outlook - StockTitan
RenovoRx begins commercialisation of RenovoCath device - Yahoo Finance
RenovoRx begins RenovoCath device sales, eyes market expansion By Investing.com - Investing.com Canada
RenovoRx begins RenovoCath device sales, eyes market expansion - Investing.com India
RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System - Markets Insider
Eupraxia Pharmaceuticals Inc (EPRX-Q) QuotePress Release - The Globe and Mail
RenovoRx announces NHCI is enrolling patients for Phase III TIGeR-PaC trial - TipRanks
RenovoRx Expands Phase III Pancreatic Cancer Trial with Major Cancer Institute Partnership | RNXT Stock News - StockTitan
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial - The Manila Times
Peripheral IV Catheters Market: Rapid Global Data Volume Growth - openPR
RenovoRx reports Q3 net loss $2.5M vs $1.4M last year - TipRanks
RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights - The Manila Times
We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully - Simply Wall St
RenovoRx (NASDAQ:RNXT) Stock Price Up 2.5% – Still a Buy? - Defense World
RenovoRx ramps up production of RenovoCath system By Investing.com - Investing.com Australia
RenovoRx ramps up production of RenovoCath system - Investing.com
RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians - GlobeNewswire
Rhumbline Advisers Has $1.23 Million Stock Holdings in The RMR Group Inc. (NASDAQ:RMR) - Defense World
Renovos Biologics Appoints New Non-Executive Director - European Pharmaceutical Manufacturer
RXO Inc (RXO) Shares Up 4.51% on Sep 19 - GuruFocus.com
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer - StockTitan
State of New Jersey Common Pension Fund D Has $2.48 Million Stock Position in RXO, Inc. (NYSE:RXO) - Defense World
Jefferies initates Ralph Lauren Corp (RL) stock to a Buy - Knox Daily
Reckitt shares up on report of potential homecare asset sale By Investing.com - Investing.com Australia
Reckitt starts talks on $7.9 bln homecare assets sale, Bloomberg News reports - XM
Federated Hermes Inc. Boosts Stock Position in The RMR Group Inc. (NASDAQ:RMR) - Defense World
Ascendiant Capital Markets Increases RenovoRx (NASDAQ:RNXT) Price Target to $8.25 - Defense World
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
RenovoRx (NASDAQ:RNXT) Trading Up 1.7% - Defense World
What was RenovoRx Inc (RNXT)’s performance in the last session? - US Post News
The time has not yet come to remove your chips from the table: RenovoRx Inc (RNXT) - SETE News
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York - StockTitan
RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024 - MSN
RenovoRx (NASDAQ:RNXT) Releases Quarterly Earnings Results - Defense World
RenovoRx continues drug-device combo Phase III trial in pancreatic cancer - Yahoo Finance
RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial - StockTitan
RenovoRx, Inc. - Stocks Telegraph
TAMP therapy shows promise in pancreatic cancer survival By Investing.com - Investing.com Nigeria
TAMP therapy shows promise in pancreatic cancer survival - Investing.com
RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist® - StockTitan
UNMC joins trial exploring new pancreatic cancer treatment - University of Nebraska Medical Center
Nektar Therapeutics (NASDAQ:NKTR) vs. RenovoRx (NASDAQ:RNXT) Critical Comparison - Defense World
RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist® - StockTitan
RenovoRx Announces Publication Of Results Of Pre-Clinical Studies Support Efficacy And Drug Delivery Mechanism ... - Quantisnow
RenovoRx CEO Updates Shareholder Letter - Quantisnow
University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC ... - StockTitan
RenovoRx (NASDAQ:RNXT) Coverage Initiated by Analysts at Ascendiant Capital Markets - Defense World
Ascendiant Capital highlights cancer therapy, sees potential on RenovoRx stock - Investing.com India
Ascendiant Capital highlights cancer therapy, sees potential on RenovoRx stock By Investing.com - Investing.com
2.88%
2.65%
자본화:
|
볼륨(24시간):